Myc proteins in brain tumor development and maintenance

Figures & data

Figure 1. Schematic model of the regulatory pathways for Myc proteins from activating signals of collaborating oncogenes to protein destabilization and proteasomal degradation. Suggested activating pathways (in red) and inhibiting pathways (in green) with putative involvement in brain tumor development and maintenance.

Table I. Few mutations of Myc genes are found in brain tumor samples^a.

Gene^b	AA mutation	CDS mutation	Sample name	Sample ID	Histology (WHO grade)
MYC	p.R316R	c.948G > A	TCGA-02-0083	1287236	Glioblastoma (IV)
MYCN	p.P365P	c.1095A > G	TCGA-02-0010	1287210	Glioblastoma (IV)
MYCN	p.P44L	c.131C > T	TCGA-02-0028	1287216	Glioblastoma (IV)

^aThe mutation data were obtained from the Sanger Institute Catalogue of Somatic Mutations in Cancer web site (as of October, 2011), http://www.sanger.ac.uk/cosmic (105), in the Primary Tissue category of Central Nervous System (CNS) tumors.

^bFor MYC, one mutation was found in 524 cases examined in the category of CNS tumors. For MYCN, two mutations were found in 469 cases examined in the category of CNS tumors. No mutations were reported for MYCL1 in the category of CNS tumors (45 cases). WHO = World Health Organization; AA = amino acid; CDS = coding sequence; TCGA = The Cancer Genome Atlas (51).

Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91:355–8.

 PubMed Web of Science ®Google Scholar

TCGA research network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.

 PubMed Web of Science ®Google Scholar